bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of “Hold” by Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) have earned a consensus recommendation of “Hold” from the eighteen analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.31.

Several equities research analysts have issued reports on the company. StockNews.com assumed coverage on bluebird bio in a report on Thursday, March 31st. They set a “sell” rating on the stock. Barclays lowered their price target on bluebird bio from $4.00 to $3.00 in a report on Tuesday, May 10th. Cowen downgraded bluebird bio from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 6th. SVB Leerink lowered their price target on bluebird bio from $10.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, April 6th. Finally, Morgan Stanley lowered their price target on bluebird bio from $6.00 to $5.00 and set an “underweight” rating for the company in a report on Monday, March 7th.

bluebird bio stock opened at $3.39 on Tuesday. The stock’s 50 day moving average price is $4.40 and its 200 day moving average price is $7.72. The firm has a market capitalization of $242.22 million, a PE ratio of -0.32 and a beta of 1.63. bluebird bio has a one year low of $3.11 and a one year high of $35.59.

bluebird bio (NASDAQ:BLUE – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). bluebird bio had a negative return on equity of 111.73% and a negative net margin of 2,183.15%. The business had revenue of $1.95 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same quarter in the prior year, the firm earned ($3.07) earnings per share. bluebird bio’s revenue for the quarter was up 117.6% compared to the same quarter last year. On average, sell-side analysts anticipate that bluebird bio will post -4.59 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of BLUE. US Bancorp DE increased its position in bluebird bio by 82.9% in the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 3,847 shares during the last quarter. Raymond James & Associates acquired a new position in bluebird bio in the 1st quarter worth about $50,000. Penserra Capital Management LLC acquired a new position in bluebird bio in the 1st quarter worth about $53,000. Bank of Montreal Can acquired a new position in bluebird bio in the 1st quarter worth about $58,000. Finally, Sanders Morris Harris LLC bought a new stake in shares of bluebird bio during the 1st quarter worth about $62,000. 96.38% of the stock is currently owned by institutional investors.

bluebird bio Company Profile (Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Recommended Stories